Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Unity Biotechnology Inc
(NQ:
UBX
)
1.480
-0.020 (-1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
71,949
Open
1.520
Bid (Size)
1.470 (268)
Ask (Size)
1.520 (30)
Prev. Close
1.500
Today's Range
1.470 - 1.520
52wk Range
1.470 - 3.480
Shares Outstanding
14,601,258
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
April 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
April 15, 2024
UBX stock results show that Unity Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-22.92%
-22.92%
1 Month
-6.33%
-6.33%
3 Month
-13.95%
-13.95%
6 Month
-17.32%
-17.32%
1 Year
-32.42%
-32.42%
More News
Read More
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
April 15, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
March 25, 2024
Via
Benzinga
Analyst Ratings for Unity Biotechnology
August 09, 2023
Via
Benzinga
The Latest Analyst Ratings for Unity Biotechnology
June 26, 2023
Via
Benzinga
Where Unity Biotechnology Stands With Analysts
May 26, 2023
Via
Benzinga
Recap: Unity Biotechnology Q1 Earnings
May 09, 2023
Via
Benzinga
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
February 06, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
January 19, 2024
Via
Benzinga
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
December 12, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Where Unity Biotechnology Stands With Analysts
April 25, 2023
Via
Benzinga
Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution
November 16, 2023
Via
Benzinga
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
November 13, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
November 10, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
October 17, 2023
Via
InvestorPlace
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
September 27, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
August 08, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
June 26, 2023
Via
Benzinga
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
June 21, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
May 09, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
April 24, 2023
Via
Benzinga
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
April 24, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
April 23, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.